Background:
As the number of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infected
people is greatly increasing worldwide, the international medical situation becomes very serious. Potential
therapeutic drugs, vaccine and stem cell replacement methods are emerging, so it is urgent to find specific
therapeutic drugs and the best treatment regimens. After the publications on hydroxychloroquine (HCQ) with anti-
SARS-COV-2 activity in vitro, a small, non-randomized, open-label clinical trial showed that HCQ treatment was
significantly associated with reduced viral load in patients with coronavirus disease-19 (COVID-19). Meanwhile, a
large prophylaxis study of HCQ sulfate for COVID-19 has been initiated in the United States. HCQ offered a
promising efficacy in the treatment of COVID-19, but the optimal administration is still being explored.
Methods:
We used the keyword "hydroxychloroquine" to conduct a literature search in PubMed to collect relevant
literature on the mechanism of action of HCQ, its clinical efficacy and safety, pharmacokinetic characteristics,
precautions for clinical use and drug interactions to extract and organize information.
Results:
This paper reviews the mechanism, clinical efficacy and safety, pharmacokinetic characteristics, exposureresponse
relationship and precautions and drug interactions of HCQ, and summarizes dosage recommendations for
HCQ sulfate.
Conclusion:
It has been proved that HCQ, which has an established safety profile, is effective against SARS-CoV-2
with sufficient pre-clinical rationale and evidence. Data from high-quality clinical trials are urgently needed
worldwide.
Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or an Olmesartan/Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China
